Mey Capital Matrix
VC Fund
München, Germany
Mey Capital Matrix is a VC fund in München focused on Health Care and Medical. The MEY Capital Matrix GmbH is a company which helps to reduce healthcare cost and provides personalized medicines.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Mey Capital Matrix invests in
Stages Mey Capital Matrix invests in
Countries Mey Capital Matrix invests in
Investment Focus
Industry
- Health Care 3 (75%)
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Organic Food 1 (25%)
- Food and Beverage 1 (25%)
Stage
- Seed 1 (25%)
- Series C 1 (25%)
- Series D 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pumpkin Organics
|
Pumpkin Organics is an innovative baby food concept that values vegetables and good healthy eating from the very first bite. Our recipes are 100% organic with nothing extra – no added sugars, salt, preservatives or additives. | $4.3M / Seed / May 17, 2023 | |
iThera Medical
|
iThera Medical offers access to innovative technology and know-how in photonic molecular imaging. The company was founded in 2010, as a spin-off from the Helmholtz Zentrum Muenchen, the German Research Center for Environmental Health (HMGU). Together, they pursue the further development of proprietary MSOT technology for use in preclinical andclinical applications. | $14.3M / Dec 21, 2022 | |
|
iThera Medical
|
iThera Medical offers access to innovative technology and know-how in photonic molecular imaging. The company was founded in 2010, as a spin-off from the Helmholtz Zentrum Muenchen, the German Research Center for Environmental Health (HMGU). Together, they pursue the further development of proprietary MSOT technology for use in preclinical andclinical applications. | $13.8M / Series D / Dec 21, 2022 | |
GNA Biosolutions
|
GNA Biosolutions is a molecular technology company based in Martinsried, Germany. Their breakthrough technology, Pulse Controlled Amplification, transforms molecular testing by combining ultrafast nucleic acid amplification with intrinsic sample prep, to enable powerful solutions for the laboratory, on-site applications and the Point of Care. Theirvision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. | $13.5M / Series C / Aug 06, 2019 |
Co-Investors
OCCIDENT
3 deals together
Wachstumsfonds Bayern
3 deals together
BayBG Venture Capital
2 deals together
Falk Strascheg Holding
2 deals together
Fluxunit - Osram Ventures
2 deals together
TRUMPF Venture
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mey Capital Matrix invest in?
Mey Capital Matrix invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series C stage. Most of the 4 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Mey Capital Matrix last invest?
The most recent investment recorded for Mey Capital Matrix closed in May 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
